Novartis' Ianalumab Receives FDA Breakthrough Therapy Designation for Sjögren's Disease
核心洞察
The FDA granted Breakthrough Therapy designation to Novartis' ianalumab for Sjögren's disease (搜索), the second most prevalent rheumatic autoimmune disease (搜索) affecting approximately 0.25% of the population.
Ianalumab is a fully human monoclonal antibody (搜索) with dual mechanism of action that depletes B-cells (搜索) and inhibits their activation via BAFF-R (搜索) blockade, potentially becoming the first targeted treatment for this condition.
The designation is supported by positive results from two global Phase III trials (NEPTUNUS-1 and NEPTUNUS-2) showing clinically meaningful benefits in disease activity reduction and patient burden.
Novartis announced that the US Food and Drug Administration has granted Breakthrough Therapy designation to ianalumab for Sjögren's disease (搜索), marking a significant regulatory milestone for what could become the first targeted treatment for this debilitating autoimmune condition. The designation is based on clinical evidence from Phase III trials demonstrating the drug's potential to substantially improve the standard of care for patients who currently lack effective treatment options.
Novel Dual Mechanism Addresses Unmet Medical Need
Ianalumab is a fully human monoclonal antibody (搜索) with a novel dual mechanism of action that depletes B-cells (搜索) and inhibits their activation and survival via BAFF-R (搜索) blockade. This approach targets key pathways involved in Sjögren's disease (搜索) pathogenesis, offering a potentially transformative therapeutic option for patients with this serious, progressive autoimmune condition.
"This Breakthrough Therapy designation recognizes the potential for ianalumab to substantially improve the standard of care for people with Sjögren's disease (搜索), who currently don't have effective treatment options for this debilitating disease," said Angelika Jahreis, Global Head, Development, Immunology, Novartis.
Significant Disease Burden and Diagnostic Challenges
Sjögren's disease (搜索) represents the second most prevalent rheumatic autoimmune disease (搜索), affecting approximately 0.25% of the population. The condition causes a wide spectrum of symptoms including dryness, fatigue, pain, and an increased risk of lymphoma (搜索), which can carry a significant burden and impact on quality of life. Its heterogeneous nature often causes it to go unrecognized or misdiagnosed, with an estimated 50% of people with Sjögren's remaining undiagnosed.
The disease affects multiple organs and currently has no approved targeted treatments available, highlighting the critical unmet medical need that ianalumab aims to address.
Phase III Trial Results Support Regulatory Decision
The FDA's Breakthrough Therapy designation is supported by positive data from multiple studies, including the replicate Phase III trials NEPTUNUS-1 and NEPTUNUS-2. These global, multicenter, pivotal studies evaluated the efficacy and safety of ianalumab in patients with Sjögren's disease (搜索).
In both trials, ianalumab delivered clinically meaningful benefits, showing improvement in disease activity and reductions in patient burden. The drug demonstrated a favorable safety profile with an overall incidence of adverse events and serious adverse events comparable to placebo in both studies.
Expedited Development Path
Building on the Fast Track designation that ianalumab received in 2016, the Breakthrough Therapy designation aims to expedite the development and review of therapies intended to treat serious conditions and address significant unmet needs. This regulatory pathway is designed to facilitate more frequent meetings with FDA to discuss the drug's development plan and ensure efficient review of marketing applications.
Novartis plans to submit ianalumab for regulatory approval globally starting in early 2026. If approved, ianalumab would become the first targeted treatment for patients with Sjögren's disease (搜索), potentially transforming the treatment landscape for this challenging autoimmune condition.